Drug intelligence / Profile preview

ODM-214

Development stage: Preclinical
Lead developer: Orion
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

ODM-214 is a bispecific antibody under preclinical development by Orion for the treatment of cancer. As a bispecific antibody, it is designed to simultaneously bind two different antigens or epitopes, potentially enhancing its therapeutic efficacy in targeting cancer cells. The specific targets and detailed mechanism of action have not been disclosed publicly as of June 2025. Development activities are currently focused in Finland[1][2][3].

Beyond the preview

Go deeper on ODM-214.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ODM-214.

Explore the full profile